Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mark Soloway
Active surveillance in low-grade NMIBC — results of an international two-round modified Delphi consensus
Abstract Standard management for recurrent low-grade non-muscle-invasive bladder cancer (LG-NMIBC) often involves a substantial treatment burden, which is not justified by the relatively indolent course of the disease, prompting a need for de-intensification strategies. Active surveillance (AS) is an alternative approach aimed at reducing overtreatment in selected patients.
The Fallacy of “Definitive Therapy” for Prostate Cancer
Mark S. Soloway Mark S. Soloway Correspondence Corresponding author. Urologic Oncology, Division of Urology, Memorial Healthcare System, 20801 Biscayne Boulevard, Aventura, FL 33180, USA. Tel.: +1 305 6822580; Fax: +1 305 7051677. Affiliations Urologic Oncology, Division of Urology, Memorial Healthcare System, Aventura, FL, USA Search for articles by this author Soum D. Lokeshwar Published:August 06, 2020DOI:https://doi.org/10.1016/j.eururo.2020.07.013
Risk‐adapted management of low‐grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)
Review Ashish M. Kamat Corresponding Author E-mail address: akamat@mdanderson.org University of Texas MD Anderson Cancer Center, Houston, TX, USA Correspondence: Ashish M. Kamat, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX 77030, USA.
Editorial: Postoperative intravesical chemotherapy has an important role in reducing subsequent bladder tumours – why is it not routine? - BJUI
Transurethral resection of bladder tumour (TURBT) is a frequent operation performed by urologists worldwide. Although on occasion the procedure can be quite challenging, the majority are relatively straightforward with little morbidity. In most cases, where the medical system allows, it is an outpatient procedure. Nonetheless, with the exception of small low‐grade tumours the patient is anaesthetised. It is costly, as the procedure requires medical clearance, an operating room team and equipment.
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
Results NMIBC trials must be designed to provide the most clinically relevant data for the specific risk category of interest (low, intermediate, or high). Specific eligibility criteria and baseline evaluations depend on the risk category being studied. For the population of patients for whom bacillus Calmette-Guérin (BCG) has failed, the type of failure (BCG unresponsive, refractory, relapsing, or intolerant) should be clearly defined to make comparisons across trials feasible.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mark
Contact Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack